How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

582 results for

Malaria Chemoprophylaxis

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

161. Economics of Malaria Prevention in United States Travelers to West Africa. (Full text)

to chemoprophylaxis regimens, consultations saved healthcare payers a per-traveler average of $14 (9-day trip) to $372 (30-day trip). For travelers, consultations resulted in a range of net cost of $20 (9-day trip) to a net savings of $32 (30-day trip). Differences were mostly driven by risk of malaria in the destination country.Our model suggests that healthcare payers save money for short- and longer-term trips, and that travelers save money for longer trips when travelers adhere to malaria recommendations (...) Economics of Malaria Prevention in United States Travelers to West Africa. Pretravel health consultations help international travelers manage travel-related illness risks through education, vaccination, and medication. This study evaluated costs and benefits of that portion of the health consultation associated with malaria prevention provided to US travelers bound for West Africa.The estimated change in disease risk and associated costs and benefits resulting from traveler adherence to malaria

2013 Clinical Infectious Diseases PubMed abstract

162. Evaluating the Ottawa Malaria Decision Aid

for decision-making; decrease decisional conflict; and affect levels of adherence to prescribed malaria chemoprophylaxis. The hypotheses of this study are that: A decision aid will improve the quality of decision-making about malaria chemoprophylaxis by decreasing decisional conflict and increasing knowledge about malaria and malaria pills. Better decision quality will result in a greater level of adherence to prescribed malaria chemoprophylaxis. Condition or disease Intervention/treatment Phase Malaria (...) (the Ottawa Malaria Decision Aid), in addition to standard medical care. Other: Ottawa Malaria Decision Aid The Ottawa Malaria Decision Aid is a tool that helps patients become involved in decision making about which malaria prophylaxis pill is right for them to take. The decision aid provides information about the options for malaria chemoprophylaxis, information about the financial costs and time required to adhere to the course of preventative medication, and clarifies personal values. The decision aid

2013 Clinical Trials

163. Safety And Immunogenicity Of Novel Candidate Blood-Stage Malaria Vaccine P27A : Phase Ia/Ib

History of living in a malaria endemic area for more than five (5) years OR living in a malaria endemic area in early childhood. For practical purposes, all regions for which malaria chemoprophylaxis is advised by travel clinic are considered malaria endemic (cf. www.safetravel.ch). Known exposure to malaria in the previous six (6) months, defined as a visit to a malaria endemic region P27A ELISA positive OR parasite ELISA antibody positive AND Known exposure to malaria in a malaria endemic area P27A (...) Safety And Immunogenicity Of Novel Candidate Blood-Stage Malaria Vaccine P27A : Phase Ia/Ib Safety And Immunogenicity Of Novel Candidate Blood-Stage Malaria Vaccine P27A : Phase Ia/Ib - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more

2013 Clinical Trials

164. Systematic review of current and emerging strategies for reducing morbidity from malaria in sickle cell disease. (Full text)

Systematic review of current and emerging strategies for reducing morbidity from malaria in sickle cell disease. Sickle cell disease (SCD) is a chronic debilitating disorder affecting erythrocytes, which is especially prevalent throughout Sub-Saharan Africa and among individuals of African descent. Because malaria is thought to be a significant cause of morbidity and mortality in patients with SCD, malaria chemoprophylaxis is often recommended for these patients. In SCD, malaria (...) chemoprophylaxis reduces malaria parasite count, anaemia and the need for blood transfusion, and improves clinical outcomes. However, the effectiveness of malaria chemoprophylaxis in the setting of SCD is based on a few studies conducted prior to the emergence of widespread antimalarial drug resistance. Consequently, it is uncertain what the optimal strategy for managing patients with SCD in malarious areas should be. Despite the widespread use of hydroxyurea in non-malarious regions, little is known about its

2013 Tropical medicine & international health : TM & IH PubMed abstract

165. Malaria

Presentation within the first month of return from travel to endemic region Delayed presentation beyond 2 months may occur with the use of chemoprophylaxis Initial prodrome Malaise Next (>50% of patients) Shaking chills Next Drowsiness Lethargy Other symptoms Myalgias More severe in Muscle tenderness More severe in and s Back pain VI. Signs for 1-8 hours recurs Plasmodium Vivax: 48 hour intervals (Tertian Fever) Plasmodium Malariae: 72 hour intervals (Quartan Fever) Plasmodium Falciparum: Variable (...) when patient is febrile Image Rapid blood dipstick testing (when smear not available) Tests HRP-2 detection (only detects P. falciparum) LDH detection (detects all 4 Malaria types) Precautions Decreased with low levels of mia Examples: Patients who took chemoprophylaxis, or prior exposure Negative rapid tests should be confirmed with blood smears Malaria PCR Detects low levels of parsites in blood (<5 s/ul) Distinguishes between plasmodium species May be used to monitor response to treatment at 5-8

2015 FP Notebook

166. Trends in the knowledge, attitudes and practices of travel risk groups towards prevention of malaria: results from the Dutch Schiphol Airport Survey 2002 to 2009. (Full text)

advice providers to create awareness and to propagate safe and healthy travel. The KAP profile of last-minute travellers, in particular, substantially increased their relative risk for malaria, underlining the continuous need for personal protective measures and malaria chemoprophylaxis for this risk group. (...) Trends in the knowledge, attitudes and practices of travel risk groups towards prevention of malaria: results from the Dutch Schiphol Airport Survey 2002 to 2009. Previous studies investigating the travellers' knowledge, attitudes and practices (KAP) profile indicated an important educational need among those travelling to risk destinations. Initiatives to improve such education should target all groups of travellers, including business travellers, those visiting friends and relatives (VFRs

2012 Malaria journal PubMed abstract

167. Imported Plasmodium falciparum malaria in HIV-infected patients: a report of two cases. (Full text)

-endemic areas and presented a parasitaemia > 5% of erythrocytes and clinical signs of severe falciparum malaria, both with > 350 CD4 cell count/μl, absence of chemoprophylaxis and successful response. Factors like drug interactions and the possible implication of anti-malarial therapy bioavailability are all especially interesting in HIV-malaria co-infections. (...) Imported Plasmodium falciparum malaria in HIV-infected patients: a report of two cases. As HIV becomes a chronic infection, an increasing number of HIV-infected patients are travelling to malaria-endemic areas. Association of malaria with HIV/AIDS can be clinically severe. Severe falciparum malaria is a medical emergency that is associated with a high mortality, even when treated in an Intensive Care Unit. This article describes two cases of HIV-positive patients, who returned from malaria

2012 Malaria journal PubMed abstract

168. The Increase of Imported Malaria Acquired in Haiti among US Travelers in 2010. (Full text)

. The demographics of travelers and the proportion of severe cases are similar to those statistics reported in previous years. Non-adherence to malaria chemoprophylaxis remains a nearly universal modifiable risk factor among these cases. (...) The Increase of Imported Malaria Acquired in Haiti among US Travelers in 2010. From 2004 to 2009, the number of malaria cases reported in Haiti increased nearly fivefold. The effect of the 2010 earthquake and its aftermath on malaria transmission in Haiti is not known. Imported malaria cases in the United States acquired in Haiti tripled from 2009 to 2010, likely reflecting both the increased number of travelers arriving from Haiti and the increased risk of acquiring malaria infection in Haiti

2012 American Journal of Tropical Medicine & Hygiene PubMed abstract

169. Incidence of Malaria among Mosquito Collectors Conducting Human Landing Catches in Western Kenya. (Full text)

. Participants were presumptively cleared of malaria with Coartem™ (artemether-lumefantrine) and tested for malaria every 2 weeks for 12 weeks. The HLC collections were conducted four nights per week for six weeks. Collectors were provided chemoprophylaxis with Malarone™ (atovaquone-proguanil) during the six weeks of HLC activities and one week after HLC activities were completed. The incidence of malaria was 96.6% lower in collectors than in non-collectors (hazard ratio = 0.034, P < 0.0001). Therefore (...) Incidence of Malaria among Mosquito Collectors Conducting Human Landing Catches in Western Kenya. The human landing catch (HLC) has long been the gold standard for estimating malaria transmission by mosquitoes, but has come under scrutiny because of ethical concerns of exposing collectors to infectious bites. We estimated the incidence of Plasmodium falciparum malaria infection in a cohort of 152 persons conducting HLCs and compared it with that of 147 non-collectors in western Kenya

2012 American Journal of Tropical Medicine & Hygiene PubMed abstract

170. Controlled Human Malaria Infection (CHMI) After Immunization With Cryopreserved Plasmodium Falciparum Sporozoites Under Chloroquine Prophylaxis

or disease Intervention/treatment Phase Malaria Plasmodium Falciparum Biological: PfSPZ Challenge Biological: Normal Saline (NS) Phase 1 Detailed Description: The study is a single centre, double blind, randomized controlled clinical trial. Volunteers, investigators and laboratory personnel will be blinded. A maximum of 30 volunteers will be randomly divided into four groups. All volunteers will receive standard weekly chloroquine chemoprophylaxis for a period of 14 weeks (98 days). During this period (...) : November 20, 2012 Last Update Posted: May 15, 2017 Last Verified: May 2014 Layout table for additional information Studies a U.S. FDA-regulated Drug Product: Yes Studies a U.S. FDA-regulated Device Product: No Keywords provided by Sanaria Inc.: Malaria Plasmodium falciparum PfSPZ Challenge Chemoprophylaxis PfSPZ-CVac Additional relevant MeSH terms: Layout table for MeSH terms Malaria Protozoan Infections Parasitic Diseases Vaccines Chloroquine Chloroquine diphosphate Immunologic Factors Physiological

2012 Clinical Trials

171. Trial for Malaria Vaccine Candidate, PfPEBS (P. Falciparum Pre-Erythrocytic and Blood Stage)

concerning contra-indications for participation in the study Willingness to undergo screening for drugs such as amphetamines, opiates and cocaine Exclusion Criteria: Any history of malaria Known exposure to malaria in the previous 6 months, defined as a visit to a malaria endemic region. For practical purposes, all regions for which malaria chemoprophylaxis is advised by travel clinic are considered malaria endemic Planned to travel to endemic malaria areas during the study period Prior administration (...) Trial for Malaria Vaccine Candidate, PfPEBS (P. Falciparum Pre-Erythrocytic and Blood Stage) Trial for Malaria Vaccine Candidate, PfPEBS (P. Falciparum Pre-Erythrocytic and Blood Stage) - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more

2012 Clinical Trials

172. Malaria suppression with fortnightly doses of pyrimethamine with sulfadoxine in the Gambia (Full text)

successful in suppressing seasonal hyperendemic malaria in a group of 38 Gambian children over a 6-month period. On the other hand, pyrimethamine alone at the recommended dose failed to suppress falciparum malaria in some children of another group. Parasite resistance to the sulfonamide-pyrimethamine combination was not encountered nor was there any suggestion of toxicity. It is concluded that these drugs in combination could have a place in malaria chemoprophylaxis. (...) Malaria suppression with fortnightly doses of pyrimethamine with sulfadoxine in the Gambia As it had been shown in previous trials that very small doses of pyrimethamine and sulfadoxine or dapsone were effective in eliminating Plasmodium falciparum in 2 or 3 days, small-scale field trials were carried out on children to investigate the efficacy of this combination of drugs in suppressing malaria.Doses of pyrimethamine 2 mg with sulfadoxine 40 mg, fortnightly, appeared to be completely

1970 Bulletin of the World Health Organization PubMed abstract

173. Studies on the toxicity and action of diaminodiphenylsulfone (DDS) in avian and simian malaria (Full text)

Studies on the toxicity and action of diaminodiphenylsulfone (DDS) in avian and simian malaria Interest in the schizontocidal activity of diaminodiphenylsulfone (DDS) and in its possible use in malaria chemoprophylaxis has recently been revived. Studies on its toxicity and action in avian and simian malaria show that its chronic toxicity in monkeys is similar to that of the established antimalarials and that it lacks causal prophylactic, gametocidal and sporontocidal activity against Plasmodium

1962 Bulletin of the World Health Organization PubMed abstract

174. High Rates of Malaria among US Military Members Born in Malaria-Endemic Countries, 2002-2010. (Full text)

High Rates of Malaria among US Military Members Born in Malaria-Endemic Countries, 2002-2010. To estimate malaria rates in association with birth country, we analyzed routine surveillance data for US military members. During 2002-2010, rates were 44× higher for those born in western Africa than for those born in the United States. Loss of natural immunity renders persons susceptible when visiting birth countries. Pretravel chemoprophylaxis should be emphasized.

2011 Emerging Infectious Diseases PubMed abstract

175. Safety, Immunogenicity and Efficacy Against of a Combined Malaria Vaccine in Healthy Malaria-naïve Adults

. Prior receipt of an investigational malaria or adenovirus vaccine. Chronic use of antibiotics with antimalarial effects. History of malaria chemoprophylaxis within 60 days prior to vaccination. Any history of malaria. Planned travel to malaria endemic areas during the study period. History of allergic disease or reactions likely to be exacerbated by any component of the vaccine(s) including latex. History of allergic disease or reactions likely to be exacerbated by chloroquine. History of psoriasis (...) Safety, Immunogenicity and Efficacy Against of a Combined Malaria Vaccine in Healthy Malaria-naïve Adults Safety, Immunogenicity and Efficacy Against of a Combined Malaria Vaccine in Healthy Malaria-naïve Adults - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100

2011 Clinical Trials

176. Malaria

for decades and lead to immune complex–mediated nephritis or nephrosis or tropical splenomegaly; when symptomatic, fever tends to occur at 72-h intervals—a quartan pattern. Manifestations in patients taking chemoprophylaxis In patients who have been taking chemoprophylaxis (see Table: ), malaria may be atypical. The incubation period may extend weeks to months after the drug is stopped. Those infected may develop headache, backache, and irregular fever, but parasites may initially be difficult to find (...) is contraindicated during pregnancy and breastfeeding, unless the infant has been shown not to be G6PD deficient. In pregnant women, chemoprophylaxis with weekly chloroquine can be given for the remainder of pregnancy, and after delivery, women can be given primaquine , provided they are not G6PD deficient. Prevention Travelers to endemic regions should be given chemoprophylaxis (see Table: ). Information about countries where malaria is endemic is available from the CDC (see and ); the information includes

2013 Merck Manual (19th Edition)

177. Determining utility values related to malaria and malaria chemoprophylaxis. (Full text)

Determining utility values related to malaria and malaria chemoprophylaxis. Chemoprophylaxis for travellers' malaria is problematic. Decision modeling may help determine optimal prevention strategies for travellers' malaria. Such models can fully assess effect of drug use and disease on quality of life, and help travellers make informed values based decisions. Such models require utility values reflecting societal preferences over different health states of relevance. To date (...) , there are no published utility values relating to clinical malaria or chemoprophylaxis adverse events.Utility estimates for health states related to falciparum malaria, sequelae and drug-related adverse events were obtained using a self-administered visual analogue scale in 20 individuals. Utility values for health states related to clinical malaria were obtained from a survey of 11 malaria experts questioned about length of hospital stay or equivalent disability with simple and severe travellers' malaria.The

2010 Malaria journal PubMed abstract

178. Cost-effectiveness analysis of malaria chemoprophylaxis for travellers to West-Africa. (Full text)

Cost-effectiveness analysis of malaria chemoprophylaxis for travellers to West-Africa. The importation of malaria to non-endemic countries remains a major cause of travel-related morbidity and a leading cause of travel-related hospitalizations. Currently they are three priority medications for malaria prophylaxis to West Africa: mefloquine, atovaquone/proguanil and doxycycline. We investigate the cost effectiveness of a partial reimbursement of the cheapest effective malaria chemoprophylaxis (...) (mefloquine) for travellers to high risk areas of malaria transmission compared with the current situation of no reimbursement.This study is a cost-effectiveness analysis based on malaria cases imported from West Africa to Switzerland from the perspective of the Swiss health system. We used a decision tree model and made a literature research on the components of travel related malaria. The main outcome measure was the cost effectiveness of malaria chemoprophylaxis reimbursement based on malaria

2010 BMC Infectious Diseases PubMed abstract

179. Relapsing vivax malaria despite chemoprophylaxis in two blood donors who had travelled to Papua New Guinea. (Abstract)

Relapsing vivax malaria despite chemoprophylaxis in two blood donors who had travelled to Papua New Guinea. Two Australian blood donors were diagnosed with relapsing Plasmodium vivax malaria 5 and 15 months, respectively, after their most recent travel to a malaria-endemic country. Common features included travel to Papua New Guinea (specifically, the Kokoda Trail); full compliance with recommended malaria chemoprophylaxis; and negative results on malaria antibody testing at the time (...) of donation. Although all fresh blood components from the two donors issued on the basis of these negative results were recalled before transfusion, these cases underscore the increased potential for relapse of P. vivax in donors returning from malaria-endemic countries, as well as the inability to identify the potential for relapse using current malarial screening tests.

2010 Medical Journal of Australia

180. The position of mefloquine as a 21st century malaria chemoprophylaxis. (Full text)

The position of mefloquine as a 21st century malaria chemoprophylaxis. Malaria chemoprophylaxis prevents the occurrence of the symptoms of malaria. Travellers to high-risk Plasmodium falciparum endemic areas need an effective chemoprophylaxis.A literature search to update the status of mefloquine as a malaria chemoprophylaxis.Except for clearly defined regions with multi-drug resistance, mefloquine is effective against the blood stages of all human malaria species, including the recently (...) recognized fifth species, Plasmodium knowlesi. New data were found in the literature on the tolerability of mefloquine and the use of this medication by groups at high risk of malaria.Use of mefloquine for pregnant women in the second and third trimester is sanctioned by the WHO and some authorities (CDC) allow the use of mefloquine even in the first trimester. Inadvertent pregnancy while using mefloquine is not considered grounds for pregnancy termination. Mefloquine chemoprophylaxis is allowed during

2010 Malaria journal PubMed abstract

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>